Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: GC Pharma Begins New Chapter For Globalization

Executive Summary

GC Pharma, formerly known as Green Cross Corp., is set to move on to the next stage of its ongoing globalization scheme with the completion of a biomanufacturing facility in Canada. Joon Soo Ryu, its vice president of office of corporate strategy, talks to Scrip about the leading Korean pharma’s North American strategy, including how it is approaching the market differently versus its Korean peers.

You may also be interested in...



GC-Yuhan Orphan Alliance Signals Changing Korean Views On Open Innovation

In what appears to be the first open innovation-based partnership between leading South Korean pharma firms, GC Pharma and Yuhan have agreed to conduct joint early research on orphan drugs, capitalizing on each others' strengths. The move may herald a shift in domestic companies' views on such collaboration and a possible increase in similar tie-ups, amid their ongoing efforts to pursue innovation.

Committing To Drug Development In World's Biggest Market: SK's Story

South Korean companies are seeking diverse ways to enter global drug markets, and SK Biopharmaceuticals is leading the way by establishing physical R&D and commercial operations in the US to progress its CNS drug pipeline. Executives of SK Life Science, the US subsidiary of SK Biopharmaceuticals, talk to Scrip about why they are committed to developing drugs in the US and what advantages and challenges they have by establishing a footprint in this key market.

US Approval Delay For Green Cross But Long Term Strategy Intact

Green Cross has hit a bump in its journey to commercialize an immunoglobulin product in the US, but analysts say the approval delay will not be a significant obstacle to its longer term North American strategy.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel